ClinicalTrials.gg
CompletedNCT06342713Updated Jun 22, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

A Phase 1 interventional study of BGB-45035 and Placebo in Healthy Participants, Healthy Subjects and Healthy Volunteers, sponsored by BeiGene. Completed at 13 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Enrollment
12th of 113
203 · median 30
Started
2024
with 25 others
Phase 1
57 of 125
40 open now
Registered
56th of 125
by date

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 12th largest by enrollment of the 113 interventional ones that give a count, is one of 26 that started in 2024, is one of 57 in phase 1, and was the 56th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This study is the first-in-human (FIH) study of BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different dose levels in healthy participants, followed by a Part E to evaluate the safety and tolerability of BGB-45035 in adults with autoimmune dermatological diseases like atopic dermatitis (AD) and prurigo nodularis (PN). An additional biomarker cohort will be evaluated in Part F.

Study details include:

  • The study duration will be up to 24 months.
  • The treatment duration will be up to 14 days for Parts A-D, up to 12 weeks for Part E, and up to 3 weeks for Part F.
  • Safety follow-up 30 days after last dose of study drug.
03

Conditions studied

  • Healthy Participants
  • Healthy Subjects
  • Healthy Volunteers
  • Autoimmune Diseases
  • Healthy Adult Participants
  • Atopic Dermatitis
  • Prurigo Nodularis

Keywords

  • Healthy Volunteers
  • Healthy Subjects
  • Healthy Participants
  • BGB-45035
  • Healthy Adult Participants
  • IL-33-induced skin inflammation
  • atopic dermatitis
  • prurigo nodularis
  • IRAK4
  • CDAC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Parts A-D and Part F:

  1. Female or male participants between the ages of 18 and 55 years inclusive (ages 18 and 45 years for Part C).
  2. of 18 to 32 kg/m\^2; and a total body weight > 50 kg (110 lbs).
  3. Evidence of a personally signed and dated document indicating that the participant has been informed of all pertinent aspects of the study.
  4. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  5. Nonsterile male participants must be willing to use a highly effective method of and refrain from sperm donation for the duration of the study and for 90 days after the last dose of study drug.
  6. Female participants of can only join Part F and must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 90 days after the last dose of study drug. They must also have a negative urine pregnancy test at baseline before first dose of study drug.

Inclusion Criteria for Part E

  1. Female or male participants between the ages of 18 to 75 years of age.
  2. Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 90 days after the last dose of study drug. They must also have a negative urine pregnancy test at baseline before first dose of study drug.
  3. AD Cohort E1:

    1. Chronic AD diagnosed by the Eichenfield revised criteria of Hannifin and Rajka that has been present for at least 1 year before the Screening Visit.
    2. Prior to baseline assessment, participants with AD must have used only nonmedicated topical emollients twice daily for at least 7 days, without any active ingredients or additives that could impact AD treatment (such as hyaluronic acid, urea, ceramide, or filaggrin degradation products). Participant's response to treatment must have remained inadequate at baseline. Additionally, the participant must be willing and able to adhere to standardized background topical therapy as outlined in the protocol throughout the remainder of the study.
  4. PN Cohort E2:

    1. Diagnosed as PN by a dermatologist for at least 3 months before the Screening Visit with prurigo lesions on upper limbs with or without lesions on the trunk or lower limbs.
    2. Minimum of 20 PN lesions in total on either of the following: both legs, both arms, and/or the trunk at the Screening Visit and on Day 1.

General Inclusion Criteria:

1. Must agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study.

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  2. Any condition possibly affecting drug absorption (eg, gastrectomy or cholecystectomy).
  3. Treatment with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product, whichever is longer.
  4. 12-lead demonstrating > 450 milliseconds.
  5. Clinically significant abnormality on chest radiograph performed at screening or within 3 months of screening date.
  6. History of tuberculosis or active or latent or inadequately treated infection, positive IGRA tests
  7. Herbal supplements (including St. John's Wort) and hormone replacement therapy must be discontinued 14 days prior to the first dose of study medication.
  8. Vaccination with live virus, attenuated live virus, or any live viral components within the 6 weeks prior to the first dose of study drug or is to receive these vaccines at any time during treatment or within 8 weeks following completion of study treatment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Part A (Single Ascending Dose)

    Part A is designed to assess the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic profile of BGB-45035 following single-ascending doses (SAD) in healthy participants.

    Drug: BGB-45035 · Drug: Placebo

  • Experimental
    Part B (Multiple Ascending Dose)

    Part B is designed to assess safety, tolerability, PK, and pharmacodynamic profile after repeated dosing of BGB-45035 in healthy participants.

    Drug: BGB-45035 · Drug: Placebo

  • Experimental
    Part C (Chinese Substudy)

    Part C is designed to assess safety, tolerability, PK, and pharmacodynamic profile after repeated dosing of BGB-45035 in healthy Chinese participants.

    Drug: BGB-45035 · Drug: Placebo

  • Experimental
    Part D (Food Effect)

    Part D is designed to assess the effect of food on BGB-45035 exposure.

    Drug: BGB-45035

  • Experimental
    Part E (AD Cohort E1)

    AD Cohort E1 is designed to assess the safety, tolerability, and efficacy of a selected dose of BGB-45035 in participants with moderate to severe AD.

    Drug: BGB-45035

  • Experimental
    Part E (PN Cohort E2)

    PN Cohort E2 is designed to assess the safety, tolerability, and efficacy of a targeted dose of BGB-45035 in participants with moderate to severe PN.

    Drug: BGB-45035

  • Experimental
    Part F (Biomarker Cohort)

    Part F is designed to assess the pharmacodynamic activity of BGB-45035 in the skin of healthy volunteers.

    Drug: BGB-45035

Interventions

  • DrugBGB-45035

    Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs) in Parts A-E

    Time frame: From the first dose of study drug to 30 days after the last dose; up to approximately 44 days for Parts A-D and up to 16 weeks for Part E

  2. Parts A-D: Number of participants with clinically significant changes from baseline in clinical laboratory values

    Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis

    Time frame: Baseline and up to approximately 1 month

  3. Parts A-D: Number of participants with clinically significant changes from baseline in vital signs

    Vital signs include blood pressure and pulse rate

    Time frame: Baseline and up to approximately 1 month

  4. Parts A-D: Number of participants with clinically significant changes from baseline in cardiac conduction intervals

    As assessed via 12-lead electrocardiogram (ECG)

    Time frame: Baseline and up to approximately 1 month

Secondary outcomes

  1. Parts A & D: Area under the plasma concentration time curve from time zero to last quantifiable time (AUClast) of BGB-45035

    Time frame: Up to approximately 14 days

  2. Parts A & D: Area under the plasma concentration time curve from time zero to infinite time (AUCinf) of BGB-45035

    Time frame: Up to approximately 14 days

  3. Parts B & C: Area under the plasma concentration time curve from time zero to end of dosing interval (AUCtau) of BGB-45035

    Time frame: Up to approximately 14 days

  4. Parts A, B, C & D: Maximum observed plasma concentration (Cmax) of BGB-45035

    Time frame: Up to approximately 14 days

  5. Parts A, B, C & D: Time to maximum plasma concentration (Tmax) of BGB-45035

    Time frame: Up to approximately 14 days

  6. Parts B & C: Trough plasma concentration (Ctrough) of BGB-45035

    Time frame: Up to approximately 14 days

  7. Parts A, B, C & D: Half life (t½) of BGB-45035

    Time frame: Up to approximately 14 days

  8. Parts A, B, & C: Apparent systemic clearance (CL/F) of BGB-45035

    Time frame: Up to approximately 14 days

  9. Parts A, B, & C: Apparent volume of distribution (Vz/F) of BGB-45035

    Time frame: Up to approximately 14 days

  10. Parts B & C: Accumulation Ratios of BGB-45035

    Time frame: Up to approximately 14 days

  11. Part E (AD Cohort E1): Change from baseline in Eczema Area and Severity Index (EASI) score at all scheduled visits

    Time frame: Baseline and up to 16 weeks

  12. Part E (AD Cohort E1): Change from baseline in Investigator Global Assessment (IGA) scale for Atopic Dermatitis (IGA-AD) score at all scheduled visits

    Time frame: Baseline and up to 16 weeks

  13. Part E (PN Cohort E2): Change from baseline in Investigator Global Assessment (IGA) Stage score at all scheduled visits

    Time frame: Baseline and up to 16 weeks

  14. Part E (PN Cohort E2): Change from baseline in Investigator Global Assessment (IGA) Activity score at all scheduled visits

    Time frame: Baseline and up to 16 weeks

  15. Part E: Change from baseline of Peak Pruritus Numerical Rating Scale (PP-NRS) at all scheduled visits

    Time frame: Baseline and up to 16 weeks

  16. Part E: Change from baseline in Average of Pruritus Numerical Rating Scale (AP-NRS) at all scheduled visits

    Time frame: Baseline and up to 16 weeks

07

Study locations

13 sites
  • Innovate Clinical Research
    Waitara, New South Wales NSW 2077, Australia
  • Cmax Clinical Research
    Adelaide, South Australia SA 5000, Australia
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100000, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 630014, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • The Affiliated Hospital of Qingdao University Branch West Coast
    Qingdao, Shandong 266555, China
  • Chengdu Second Peoples Hospital
    Chengdu, Sichuan 610021, China
  • Optimal Clinical Trials Ltd
    Auckland, 1010, New Zealand
  • Pacific Clinical Research Network Auckland
    Takapuna, 0622, New Zealand
  • Lakeland Clinical Trials Wellington
    Upper Hutt, 5018, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2026, 23 months.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 23 months is above that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Jun 20, 2024
Primary completionActual
Jun 2, 2026
CompletionActual
Jun 2, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342713
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Jun 20, 2024
Primary completion
Jun 2, 2026
Completion
Jun 2, 2026
Last update
Jun 22, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion